Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: A case report Article Conference Paper uri icon


MeSH Major

  • Astrocytoma
  • Brain Neoplasms
  • Glioblastoma
  • Quinazolines


  • We report the successful treatment of a patient with recurrent malignant glioma with adoptive cellular immunotherapy. The patient is a young adult with recurrent progressive disease refractory to aggressive multi-modality therapy including repetitive surgical resection, radiation, radiosurgery and chemotherapy. He received multiple courses of local administration of autologous lymphokine-activated killer (LAK) cells in combination with a low dose of interleukin-2 (IL-2) through an Ommaya reservoir-catheter system. The side-effects of this treatment were limited and manageable. The patient achieved a complete remission, as demonstrated by MRI and confirmed by glucose-positron emission tomography (PET) imaging 11 months after initiation of immune therapy. Twenty-six months later, the patient is still in remission with improving performance status. Adoptive cellular immunotherapy utilizing autologous LAK cells with low dose IL-2 appears to be a safe and effective therapy for a subset of patients with primary, recurrent or progressive malignant glioma following conventional therapy.

publication date

  • July 4, 2001



  • Conference Paper


Digital Object Identifier (DOI)

  • 10.1016/S1040-8428(01)00120-2

PubMed ID

  • 11418298

Additional Document Info

start page

  • 17

end page

  • 23


  • 39


  • 1-2